Title: Incidence of Symptoms Associated with Post-Acute Sequelae of SARS-CoV-2 infection □ in Non-Hospitalized Vaccinated Patients Receiving Nirmatrelvir-Ritonavir □
Authors: Rushin Patel MD^1 , Sourbha Dani MD^2 , Sumanth Khadke, MD^2 , Javaria Ahmad MD^2 , Jui Shah MD^2 Neev Mehta MD MPH 3 , Kenneth Wener MD^4 , Daniel P McQuillen MD^4 , George Abraham MD MPH 5 , Jeremy Faust MD^6 , Jason Maley, MD^7 , Smita Patel MD^8 , Janet Mullington MD^7 , Robert M. Wachter MD^9 , Anne Mosenthal MD^{10} , Paul E. Sax MD^{11*} , Sarju Ganatra MD^{2*}
□ *Authors have contributed equally□
Affiliations: □ □
1. Department of Internal Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health Burlington, Massachusetts, USA□
2. Department of Cardiovascular Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health Burlington, Massachusetts, USA□
3. Department of Gastroenterology, Lahey Hospital and Medical Center, Beth Israel Lahey Health Burlington, Massachusetts, USA□
4. Department of Infectious Disease, Lahey Hospital and Medical Center, Beth Israel Lahey Health Burlington, Massachusetts, USA□
5. Division of Infectious Disease, Department of Medicine, Saint Vincent Hospital, Worcester Massachusetts, USA□
 6. Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA□ 7. Department of Neurology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA□ 8. Department of Psychiatry, Lahey Hospital and Medical Centre, Beth Israel Lahey Health, Burlington
Massachusetts, USA
 Department of Medicine, University of California San Francisco, San Francisco, California, USA□ Department of Academic Affairs, Lahey Hospital and Medical Center, Tufts University School of Medicine Purlington Messagehyaetts USA□
 Medicine, Burlington, Massachusetts, USA□ 11. Division of Infectious Disease, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA□
Word count: □2806
Funding: None□ Disclosures: None□
Key Points: Assessment of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-
CoV-2 infection (PASC) based on broad and narrow definitions in non-hospitalized vaccinated nations

between 30-180 days and 90-180 days.

Please address correspondence to:
Sarju Ganatra, MD□
Landsman Heart and Vascular Center□
Division of Cardiovascular Medicine □
Lahey Hospital and Medical Center□
Beth Israel Lahey Health □
41 Mall Road, Burlington, MA 01805 □
Ph: 781-744-5100□
Email: Sarju.Ganatra@Lahey.org
Twitter: @SarjuGanatraMD□
Acknowledgments: None □

Abstract

Background:

The role of Nirmatrelvir plus ritonavir (NMV-r) in preventing post-acute sequelae of SARS-CoV-2 infection

(PASC) is unknown. The objective of this study is to assess the effect of NMV-r in non-hospitalized, vaccinated

patients on the occurrence of PASC.

Methods:

We performed a comparative retrospective cohort study utilizing data from the TriNetX research network,

including vaccinated patients ≥18 years old who subsequently developed Covid-19 between December 2021-

April 2022. Cohorts were based on NMV-r administration within five days of diagnosis. Based on previously

validated broad and narrow definitions, the main outcome was the presence of symptoms associated with

PASC. Outcomes were assessed between 30-180 days and 90-180 days after the index Covid-19 infection.

Results

1,004 patients remained in each cohort after propensity-score matching. PASC (broad definition) occurred in

425 patients (42%) in the NMV-r cohort, vs. 480 patients (48%) in the control cohort (OR 0.8 CI 0.67-0.96;

p=0.01) from 30-180 days and in 273 patients (27%) in the NMV-r cohort, as compared to 347 patients (35%)

in the control cohort (OR 0.707, CI 0.59-0.86; p<0.001) from 90-180 days. Narrowly defined PASC was

reported in 337 (34%) patients in the NMV-r and 404 (40%) in the control cohort between 30-180 days

(OR=0.75, CI 0.62-0.9, p=0.002) and in 221 (22%) in the NMV-r cohort as compared to in 278 (28%) patients

in the control cohort (OR=0.7, CI 0.63-0.9, p=0.003) between 90 -180 days.

Conclusions

NMV-r treatment in non-hospitalized vaccinated patients with Covid-19 was associated with a reduction in the

development of symptoms commonly observed with PASC and healthcare utilization.

Introduction

Background

Coronavirus Disease 2019 (Covid-19) caused by the SARS-CoV-2 virus can present with varied clinical presentations ranging from an asymptomatic or mildly symptomatic disease that can be managed in the outpatient setting to severe illness requiring hospitalization. In addition to acute illness, Covid-19 can result in a lingering long-term cluster of symptoms lasting for months [1]. Numerous terms, including "long Covid," "post-Covid condition," and post-acute sequelae of SARS-CoV2 infection (PASC), have been used to describe these syndromes. According to the World Health Organization, as of August 2022, 581 million people worldwide have recovered from Covid-19 [2]. The reported prevalence of PASC is 6% to 54% [3, 4], with this wide variation due to variable definitions of PASC and different populations studied. Even with the lower prevalence estimate, these numbers suggest a staggering global disease burden, making it a condition with enormous medical, public health, and economic consequences.

Advances in vaccination and therapies, along with the impact of widespread immunity acquired from prior infection, have markedly lowered the case-fatality rate of Covid-19. In addition, a significant advance has been the availability of effective outpatient therapeutics, including nirmatrelvir plus ritonavir (NMV-r) [5], molnupiravir [6], remdesivir [7], and various monoclonal antibodies [8]. \Box However, while the efficacy of these treatments in lowering the risk of acute Covid has been well established, there are currently no published data in peer-reviewed literature regarding their effectiveness in reducing the frequency of PASC. \Box

Of the available options for outpatient management of Covid-19, NMV-r is a favored treatment based on the results of a pivotal placebo-controlled trial in unvaccinated patients with the mild-moderate disease [5]. In this study, NMV-r resulted in an 89% reduction in risk of hospitalization or all-cause mortality compared to the placebo, leading to the Emergency Use Authorization of the drug [5]. Additionally, in several observational studies, NMV-r treatment was associated with reduced all-cause mortality, emergency room (ER) visits, and

hospitalizations in broader patient groups, including high-risk vaccinated Covid-19 patients (45% relative risk reduction) [9].

Objective

Given the frequency and consequences of PASC, determining whether antiviral therapy is effective in preventing PASC is of great importance. While ideally, these data would come from prospective randomized placebo-controlled clinical trials; such studies have not yet reported these outcomes with sufficient follow-up to answer this question. To address this data gap, we utilized the electronic health records (EHR)-based, curated real-world data of the TriNetX research network[10] to describe the frequency of PASC-associated symptoms among those treated versus not treated with NMV-r.

$Methods \square$

Study Oversight □

Data analysis and review of manuscripts were performed by all the above authors. Institutional review board (IRB) approval was exempted from Lahey Clinic IRB as deidentified data was obtained from a research network database. The study findings are reported per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies.

Data Source and Study Setting

This study utilized the TriNetX Analytics Network – Research Network, a multicenter federated health research network using de-identified data from electronic health records (EHRs) from participating healthcare organizations, including academic medical centers and specialty physician practices, and community hospitals. The research network contains data on more than 88 million patients. While the data are in aggregate de-identified form, the built-in analytics allows for the generation of patient-level data for cohort selection and matching, analyzing incidence and prevalence of events in a cohort, and comparing characteristics and outcomes between matched cohorts. More information on the database can be found online [10].

Study Population and Design□

RxNorm terminology. \Box

The TriNetX research network was searched, and data curation was performed on October 17, 2022. A comparative retrospective cohort study was conducted, which included non-hospitalized patients ≥18 years who were vaccinated and subsequently developed Covid-19 between December 1, 2021, and April 17, 2022, at least one month after vaccination. Key exclusion criteria were treatment with a monoclonal antibody, convalescent plasma, or molnupiravir for the index case of Covid-19 and hospitalization for Covid-19. Patients were further categorized based on whether they were prescribed NMV-r within five days of diagnosis. □

Patients with PASC were identified using two definitions based on the ICD code. Validated diagnostic, procedure and laboratory codes were utilized to define the vaccination status and Covid-19 diagnosis.

Identification of patients who were prescribed NMV-r was completed using the National Library of Medicine

Cohorts were matched using propensity score matching (PSM). Outcomes were analyzed from 30 to 180 days and between 90 to 180 days after the index diagnosis of Covid-19. The Supplementary Appendix provides additional inclusion and exclusion criteria and information. Study Endpoints/variables *Main Composite Endpoint* \square Since no validated diagnostic tests exist, PASC is defined by patient-reported symptoms. To account for the lack of a standard definition and the wide range of estimates on the prevalence of PASC after Covid-19, we defined PASC both broadly and narrowly, using prior published reports [11, 12]. 1) Broadly-defined PASC: included a list of the constitutional, cardio-respiratory, gastrointestinal, musculoskeletal, and nervous system, and/or mood/cognitive disorder symptoms [11]. 2) Narrowly-defined PASC: includes fatigue with myalgia or mood disorder symptoms, cognitive disorder, or respiratory symptoms [12]. Other outcomes, including complications and healthcare utilization, were also defined using validated $codes. \square \square$ In addition to the absence of a specific diagnostic test, there is a lack of agreement regarding how long symptoms persist after Covid-19 qualify as PASC. Therefore, the outcomes were analyzed beyond the first 30 days, beyond the first 90 days, and up to a total of 180 days following the index diagnosis of Covid-19. *Other Endpoints* Secondary endpoints included individual symptoms of PASC. We also assessed healthcare utilization, including diagnostic imaging and cardiovascular testing.

Statistical Analysis □

Non-hospitalized vaccinated patients who developed Covid-19 at least four weeks after vaccination were divided into two cohorts based on their use of NMV-r within five days of diagnosis. These two cohorts (NMV-r and non-NMV-r cohorts) were compared using independent sample t-tests for continuous variables, which are reported as mean (range). Categorical variables are reported as counts (%) and compared using the Chi-square $(\chi 2)$ test. To control for baseline differences in the patient cohorts, we performed 1:1 Propensity Score matching (PSM) for characteristics of clinical relevance utilizing a built-in algorithm that uses the greedy nearest-neighbor algorithm with a caliper of 0.1 pooled standard deviations. First, symptoms of PASC seen between 30 to 180 days after developing Covid-19 were assessed. Subsequently, symptoms of PASC seen between 90 to 180 days were also assessed. Any characteristic with a standardized mean difference between cohorts lower than 0.1 was considered well-matched. After propensity matching, odds ratios with 95% confidence intervals were calculated for primary and secondary outcomes using the $\chi 2$ for the measures of association. Relative risk reduction was calculated as the division of the absolute risk reduction between the treatment (NMV-r) and control (non-NMV-r) cohorts by the absolute risk of the control group. Statistical analyses were completed using the TriNetX online platform using R for statistical computing.

Role of Funding Source:

No Funding Source is involved.

Results \square

<u>Study Population</u> □

279,380 vaccinated individuals who tested positive for Covid-19 and were not hospitalized during the study were identified. Of these, 1,004 were treated with NMV-r within five □days of diagnosis and had sufficient follow-up for inclusion, and 278,376 were not treated with NVM-r. After propensity score matching, 1,004 patients were included in each cohort (Figure 1). □ □

Patient Demographics □

Table 1 outlines the baseline characteristics of each cohort before and after propensity matching. Before propensity matching, the mean age of patients treated with NMV-r was higher (mean age 57.2 ± 16.7 versus 49.7 ± 18.0 ; SD 0.430), and there were racial differences - the proportion of the Caucasian population was higher in the NMV-r cohort compared to non-NMV-r cohort (82.0% in NMV-r vs. 69.7%). In contrast, the proportion of African Americans was higher in the non-NMV-r cohort (17.1% in non-NMV-r vs. 7.9% in NMV-r). In addition, patients in the NMV-r cohort had a higher prevalence of cardiovascular risk factors

(hypertension, hyperlipidemia, diabetes mellitus). Compared to the comparison cohort, more patients were on medications for cardiovascular disease (beta-blockers, diuretics, ACE inhibitors, ARBs, aspirin, statins). In the NMV-r cohort, the prevalence was also higher for neoplasms, systemic connective tissue disorders, and chronic lower respiratory disease.

All baseline characteristics between the two cohorts, including healthcare utilization, were propensity matched, with no residual difference (standard difference for all included covariates was <0.1).

Main Outcome: □

Between 30 to 180 days post-infection: □

For broadly defined PASC-associated symptoms, vaccinated patients treated with NMV-r within five □days of developing Covid-19 had lower odds of developing persistent or new PASC-associated symptoms. For example, PASC-associated symptoms occurred in 425 patients (42%) in the NMV-r cohort, as compared to 480 patients (48%) in the control cohort (OR 0.8 CI 0.67-0.96; p=0.01) between 30 to 180 days (OR=0.8, 95% CI 0.67-0.96, p=0.01). Similarly, for a narrow definition of PASC to three □ symptom cluster, the use of NMV-r within five □days of development of Covid-19 was associated with lower odds of development of PASC-associated symptoms, which was recorded in 337 (34%) patients in the NMV-r and 404 (40%) of patients in the control cohort between 30 and 180 days (OR=0.75, CI 0.62-0.9, p=0.002). □

Between 90 to 180 days post-infection: □

Even upon modifying the timeline for the development of new or persistent PASC-associated symptoms between 90 to 180 days, patients treated with NMV-r within five □days of diagnosis had lower odds of having persistent or new PASC-associated symptoms. Broadly defined PASC-associated symptoms occurred in 273 patients (27%) in the NMV-r cohort, as compared to 347 patients (35%) in the control cohort (OR 0.707, CI 0.59-0.86; p<0.001) from 90 to 180 days. In addition, narrowly defined PASC-associated symptoms based on three □ symptom cluster was reported in 221 (22%) in the NMV-r cohort as compared to 278 (28%) patients in the control cohort (OR=0.7, CI 0.63-0.9, p=0.003).

Other Outcomes:

Between 30 to 180 days post-infection: □

Patients who had been treated with NMV-r within five days of infection with Covid-19 had lower odds of

having cardiovascular and respiratory symptoms (OR=0.72, CI 0.59-0.88, p=0.001); gastrointestinal symptoms

(OR= 0.79, CI 0.63-0.98, p=0.03); and lower anxiety/mood disorders (OR=0.77, CI 0.63-0.94, p=0.01) between

30 to 180 days post-infection. ☐ There was no difference in constitutional and musculoskeletal, and nervous

system symptoms. Cardiovascular testing was performed less frequently among those treated with NMV-r.

However, there was no significant difference in the use of radiology diagnostic tests or ambulatory/virtual

visits.

Between 90 to 180 days post-infection □

Patients who had been treated with NMV-r within five ages of infection with Covid-19 had lower odds of

having cardiovascular and respiratory symptoms (OR=0.72, CI 0.57-0.93, p=0.01); gastrointestinal symptoms

(OR= 0.65, CI 0.49-0.84, p=0.001); anxiety/mood disorders (OR=0.69, 95% CI 0.55-0.88, p=0.002) and lower

healthcare utilization including radiology and cardiovascular diagnostic tests and ambulatory/virtual visits

between 90- and 180-days post-infection. □

Discussion:

Key Results

Our exploratory retrospective study of patients from a real-world population developing Covid-19 showed that

use of NMV-r within five days of Covid-19 diagnosis was associated with 11 to 21% relative risk reduction for

developing PASC-associated symptoms. A strength of this analysis is that it included only vaccinated patients

who contracted Covid-19 when the Omicron variant was widely circulating, making it reflective of the current

status of both the population's high level of vaccine- or infection-induced immunity and the potential for

Omicron to cause less severe disease than prior variants. This relative decrease in reported symptoms with

treatment was observed using broad and narrow definitions of PASC symptoms between 30 to 180 days and 90 to 180 days. Cardiovascular, respiratory, gastrointestinal, and mood/cognitive disorder-related symptoms were recorded less frequently among those prescribed NMV-r than those not treated with NMV-r. No significant difference was noted for constitutional, musculoskeletal, and nervous system-related symptoms. Overall healthcare utilization, including radiology and cardiovascular diagnostic tests and ambulatory/virtual visits, was lower among those who received NMV-r.

Both quantitative and qualitative studies have demonstrated the complexity of diagnosing PASC in clinical settings. In addition, there are discrepancies in the definition of PASC, even among the National Institute of Health's Researching COVID to Enhance Recovery (RECOVER) Initiative and the World Health Organization [11-13]. Therefore, to overcome some of the existing variability, we emphasize that our study does not explicitly address the diagnosis of PASC but uses the reporting of PASC-associated symptoms as an outcome. We further evaluated the reporting of these symptoms using two separate timelines 1) beyond the first 30 days and 2) beyond the first 90 days after the index diagnosis of Covid-19.

The pathophysiology of PASC remains uncertain, and no drugs have proven beneficial in its prevention or treatment. There is some correlation between initial disease severity and the likelihood of developing PASC, though even some people with mild Covid-19 can experience prolonged and disabling symptoms [3, 14]. There is evidence that vaccination reduces the incidence of PASC by 15-50% [15], and the incidence also appears to be lower with Omicron compared with infection with earlier variants [16]. Both these observations could result from reduced disease severity in people vaccinated and/or acquiring Omicron, a reduced severity explained by immunologic and viral factors. A small study demonstrated that patients diagnosed with PASC had evidence of persistent SARS-CoV-2 antigen detected in blood samples [14], raising the possibility of a future diagnostic test confirming PASC and potential interventions that reduce viral replication or the duration of acute disease will reduce the risk of PASC. A study of NMV-r treatment in people with PASC is ongoing [17].

Our results are similar to those reported in the study by the Department of Veterans Affairs [18]. However, in contrast with that study, our definition of PASC-associated symptoms is more diverse. Our patient population includes only those vaccinated, a much higher proportion of women (64%), and a longer follow-up period. The inclusion of more women in our study is vital, as PASC appears to be more common in women. The reason for this difference in incidence based on sex is unknown but has also been reported in diverse autoimmune conditions, raising the possibility of autoimmunity or immune dysregulation playing a vital role in the pathogenesis of PASC.

Limitations

It is important to emphasize that, despite these observed favorable associations between NMV-r and reduced long-term symptoms, these data cannot prove that antiviral treatment reduces the incidence of PASC. As in many observational studies, the group receiving treatment differed significantly from those not receiving treatment, differences that could influence the results independent of the treatment they received. These biases could increase the risk of PASC in those accessing treatment and, conversely, decrease it. More severe symptoms could trigger reaching out for treatment and subsequent healthcare utilization, making PASC more likely in those receiving treatment. By contrast, patients who initially did not seek treatment but then later progressed may have fallen out of the 5 days from symptom onset treatment eligibility, rendering them unable to get NMV-r. While we controlled for differing baseline characteristics using propensity matching, residual confounding remains a significant potential limitation.

Several additional limitations intrinsic to the study design and the condition deserve mention. The retrospective design relied on the accuracy of the data entered in the EHR by point-of-care clinical providers; hence despite separately analyzing data for both broad and narrow-based PASC-associated symptoms, our definition may have lacked precision and may have been too inclusive. An intrinsic challenge in the study of PASC is the highly variable nature of the condition, which may involve multiple organ systems and a vast range of clinical severity, from mild fatigue to complete disability and no established diagnostic test or tests. Evidence for the

condition's heterogeneity is clear from the broad ranges reported for its incidence after Covid-19, from 6 to 54% [3] [4].

Limitations notwithstanding, our study supports the hypothesis that treating the acute infection with NMV-r may reduce the symptoms associated with PASC. It furthermore should reassure prescribers that treatment does not *increase* this risk; a potential concern given the widely observed viral and symptomatic rebound phenomenon. While a more accurate assessment of the effect of NMV-r treatment on the incidence of PASC would optimally come from the original placebo-controlled trials, EPIC-HR [5] and EPIC-SR [19], these analyses have not yet been conducted or reported. Studies of long-term outcomes are planned in more recent randomized trials, including COVID-OUT [20], ACTIV-6 [21], and PANORAMIC [22].

Interpretation

In a retrospective analysis looking at long-term outcomes after diagnosis of Covid-19, these data show an association between treatment with NMV-r and a reduced incidence of the symptoms commonly reported with PASC. As the case severity of Covid-19 is much lower than when the pandemic first started, outcomes aside from hospitalization and death must be rigorously analyzed. As such, prospective studies of the potential effect of antiviral therapy on the incidence of PASC are urgently needed. □But, pending these data, our study does support the use of NMV-r to decrease even potential long-term complications of Covid-19, an important observation given the continued low rate of prescribing for this medication.

References:

- 1. del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA **2020**; 324(17): 1723-4.
- 2. Elfein J. Number of coronavirus (COVID-19) cases, recoveries, and deaths worldwide. Available at: https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-worldwide/#main-content. Accessed 20 November 2022.
- 3. CDC. Long COVID or Post-COVID Conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html@ Accessed 20 November 2022.
- 4. Rando HM, Bennett TD, Byrd JB, et al. Challenges in defining Long COVID: Striking differences across literature, Electronic Health Records, and patient-reported information. medRxiv **2021**.
- 5. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med **2022**; 386(15): 1397-408.
- 6. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med **2022**; 386(6): 509-20.
- 7. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med **2022**; 386(4): 305-15.
- 8. Administration FaD. FDA Authorizes New Monoclonal Antibody for Treatment of COVID-19 that Retains Activity Against Omicron Variant. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains. Accessed 20 November 2022.
- 9. Ganatra S, Dani SS, Ahmad J, et al. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases **2022**.
- 10. TriNetX. The global health research network. Available at: https://trinetx.com/about-trinetx/community/. Accessed 20 November 2022.
- 11. Control CfD. Post-COVID Conditions: Information for Healthcare Providers. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html. Accessed 20 November 2022.
- 12. Organization WH. Post COVID-19 condition (Long COVID). Available at:

 https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=Definition,explained%20by%20an%20alternative%20diagnosis. Accessed 20 November 2022.
- 13. RECOVER. Explore Research. Available at: https://recovercovid.org/research.
- 14. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis **2022**.
- 15. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med **2022**; 28(7): 1461-7.
- 16. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet **2022**; 399(10343): 2263-4.
- 17. University S. Paxlovid for Treatment of Long Covid (STOP-PASC).
- 18. Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. medRxiv **2022**: 2022.11.03.22281783.
- 19. Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05011513.
- 20. Minnesota Uo. COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19). Available at: https://clinicaltrials.gov/ct2/show/NCT04510194.
- 21. ACTIV-6: COVID-19 Study of Repurposed Medications. Available at: https://clinicaltrials.gov/ct2/show/NCT04885530.

22. NHS. PANORAMIC national study. Available at: https://digital.nhs.uk/coronavirus/panoramic-trial

.

Figure Title and Legends

Figure 1: CONSORT diagram.

This figure illustrates the proportion of vaccinated, non-hospitalized patients who tested positive for SARS-CoV-2 infection or were diagnosed with Covid-19 stratified by the use of NMV-r. Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; Covid-19, coronavirus disease 2019; HCO, healthcare organization; NMV-r, nirmatrelvir plus ritonavir; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure 2. Forest Plot (30-180 Days)

This forest plot depicts the primary and secondary outcomes within 30-180 days after the diagnosis of Covid-19.

Abbreviations, PASC: post-acute sequelae of SARS-CoV-2 infection; CV: Cardiovascular; MSK: Musculoskeletal

Figure 3. Forest Plot (90-180 Days)

This forest plot depicts the primary and secondary outcomes within 90-180 days after the diagnosis of Covid-19.

Abbreviations, PASC: post-acute sequelae of SARS-CoV-2 infection; CV: Cardiovascular; MSK: Musculoskeletal

Table 1. Baseline Characteristics

	Before Pro	pensity matching	After Propensity Matching			
Baseline Characteristics	Received NMVr (n=1004)	No NMVr (n=278,376)	SD	Received NMVr (n=1004)	No NMVr (n=1004)	SD
		Demograph	nics			
Mean Age	57.2 +/- 16.7	49.7 +/- 18.0	0.430	57.2+/-16.7	56.7 +/- 16.6	0.028
Female	644 (64.1%)	172,955 (62.1%)	0.042	644 (64.1%)	661 (65.8%)	0.036
Caucasian	823 (82.0%)	194,158 (69.7%)	0.289	823 (82.0%)	801 (79.8%)	0.056
African American	79 (7.9%)	47,520 (17.1%)	0.281	79 (7.9%)	84 (8.4%)	0.018
Non-Hispanic/Latino	795 (79.2%)	166,061 (59.7%)	0.434	795 (79.2%)	794 (79.1%)	0.002
		Prior Healthcare	Utilization			
Ambulatory Visit	979 (97.5%)	219,296 (78.8%)	0.605	979 (97.5%)	979 (97.5%)	< 0.001
ER Visit	484 (48.2%)	129,143 (46.4%)	0.036	484 (48.2%)	500 (49.8%)	0.032
Hospital Inpatient Services	204 (20.3%)	45,112 (16.2%)	0.107	204 (20.3%)	199 (19.8%)	0.012
Hospital Observation Services	109 (10.9%)	24,021 (8.6%)	0.075	109 (10.9%)	116 (11.6%)	0.022
Critical Care Services	46 (4.6%)	12,413 (4.5%)	0.006	46 (4.6%)	45 (4.5%)	0.005
		Comorbidi	ties			
Hypertension	573 (57.1%)	112,181 (40.3%)	0.340	573 (57.1%)	587 (58.5%)	0.028
Hyperlipidemia	547 (54.5%)	102,803 (36.9%)	0.358	547 (54.5%)	524 (52.2%)	0.046
Diabetes Mellitus	243 (24.2%)	55,360 (19.9%)	0.104	243 (24.2%)	239 (23.8%)	0.009
Chronic Lower Respiratory Disease	332 (33.1%)	66,278 (23.8%)	0.206	332 (33.1%)	343 (34.2%)	0.023
Chronic Kidney Disease	110 (11.0%)	29,014 (10.4%)	0.017	110 (11.0%)	101 (10.1%)	0.029
Atrial Fibrillation/ Flutter	49 (4.9%)	16,769 (6.0%)	0.050	49 (4.9%)	50 (5.0%)	0.005
Ischemic Heart Disease	192 (19.1%)	37,046 (13.3%)	0.158	192 (19.1%)	190 (18.9%)	0.005
Heart Failure	56 (5.6%)	19,606 (7.0%)	0.060	56 (5.6%)	54 (5.4%)	0.009
Ischemic Stroke	56 (5.6%)	13,684 (4.9%)	0.030	56 (5.6%)	52 (5.2%)	0.018
Malignancy	463 (46.1%)	91,001 (32.7%)	0.277	463 (46.1%)	436 (43.4%)	0.054
Demyelinating Disease	22 (2.2%)	2,376 (0.9%)	0.109	22 (2.2%)	11 (1.1%)	0.086
Systematic Connective Tissue Disorder	90 (9.0%)	12,018 (4.3%)	0.187	90 (9.0%)	70 (7.0%)	0.074
BMI > 30	31.6 +/- 7.2	30.4 +/- 7.2	0.177	31.6 +/- 7.2	31.3 +/- 7.8	0.043
		Medicatio	ns			
Beta Blockers	366 (36.5%)	74,596 (26.8%)	0.209	366 (36.5%)	372 (37.1%)	0.012
Diuretics	348 (34.7%)	69,406 (24.9%)	0.214	348 (34.7%)	344 (34.3%)	0.008

ACE inhibitors	213 (21.2%)	46,596 (16.7%)	0.114	213 (21.2%)	198 (19.7%)	0.037
Angiotensin Receptor Blocker	201 (20.0%)	36,065 (13.0%)	0.191	201 (20.0%)	204 (20.3%)	0.007
Aspirin	296 (29.5%)	59,906 (21.5%)	0.183	296 (29.5%)	298 (29.7%)	0.004
Anticoagulants	285 (28.4%)	67,466 (24.2%)	0.094	285 (28.4%)	274 (27.3%)	0.024
Statin	388 (38.6%)	78,077 (28.0%)	0.226	388 (38.6%)	374 (37.3%)	0.029
Immune Suppressants	54 (5.4%)	12,390 (4.5%)	0.043	54 (5.4%)	47 (4.7%)	0.032
Antineoplastics	141 (14.0%)	27,247 (9.8%)	0.132	141 (14.0%)	139 (13.8%)	0.006
Antidepressant	427 (42.5%)	95,556 (34.3%)	0.169	427 (42.5%)	469 (46.7%)	0.084
		Laboratory '	Tests			
Hemoglobin (g/dL)	13.6 +/- 1.6	13.3 +/- 1.9	0.178	13.6 +/- 1.6	13.4 +/- 1.8	0.100
Platelets (10*3/uL)	252.0 +/- 75.7	255.6 +/- 78.5	0.047	252.0 +/- 75.7	255.9 +/- 75.5	0.052
Creatinine (mg/dL)	0.9 +/- 0.3	1.0 +/- 2.4	0.074	0.9 +/- 0.3	0.9 +/- 0.6	0.081
Total Cholesterol (mg/dL)	180.0 +/- 40.3	178.2 +/- 43.5	0.042	180.0 +/- 40.3	178.0 +/- 44.7	0.046
LDL (mg/dL)	101.3 +/- 34.0	102.0 +/- 35.8	0.021	101.3 +/- 34.0	102.3 +/- 36.2	0.029
Triglyceride (mg/dL)	129.0 +/- 83.3	120.8 +/- 105.2	0.086	129.0 +/- 83.3	128.0 +/- 88.8	0.012
Hemoglobin A1c	6.0 +/- 1.3	6.2 +/- 1.7	0.123	6.0 +/- 1.3	6.0 +/- 1.4	0.023
Left Ventricular Ejection Fraction (LVEF) (%)	60.0 +/- 11.2	57.4 +/- 13.0	0.218	60.0 +/- 11.2	60.0 +/- 11.0	0.004

Abbreviations: ACE – Angiotensin Converting Enzyme, BMI – Body Mass Index, LDL – Low-Density Lipoprotein, SD – Standard Difference

Table 2: PASC Outcomes 30-180 Days


Outcomes (30-180 Days)	Received NMVr (n=1004)	No NMVr (n=1004)	Risk difference	Relative Risk Reduction	Odds ratio	P-value
			Primary Outcome			
Broadly defined PASC	425	480	-0.055 (-0.098, -0.011)	11.46%	0.801 (0.672, 0.956)	0.014
Narrowly defined PASC	337	404	-0.067 (-0.109, -0.025)	16.58%	0.750 (0.626, 0.900)	0.002
			Secondary Outcomes			
			Individual Symptoms			
Constitutional symptoms	180	192	-0.012 (-0.046, 0.022)	6.25%	0.924 (0.738, 1.157)	0.491
CV and respiratory symptoms	219	281	-0.062 (-0.099, -0.024)	22.06%	0.718 (0.586, 0.880)	0.001
Gastrointestinal symptoms	175	212	-0.037 (-0.071, -0.002)	17.45%	0.789 (0.631, 0.985)	0.036
Nervous system and MSK symptoms	71	87	-0.016 (-0.039, 0.008)	18.39%	0.802 (0.579, 1.112)	0.185
Anxiety/mood disorder	248	299	-0.051 (-0.090, -0.012)	17.06%	0.773 (0.635, 0.942)	0.011
			Healthcare Utilization			
Radiology diagnostic tests	267	304	-0.037 (-0.076, 0.003)	12.17%	0.834 (0.687, 1.013)	0.067
CV tests (Echocardiogram and ambulatory rhythm monitors)	41	68	-0.027 (-0.047, -0.007)	39.71%	0.586 (0.394, 0.872)	0.008
AMB/Virtual Visit	747	746	0.001 (-0.037, 0.039)	0.13%	1.005 (0.823, 1.228)	0.959

Abbreviations: ER – Emergency Room, GI – Gastrointestinal

TABLE 3. PASC Outcomes 90-180 Days

Outcomes (90-180 days)	Received NMVr (n=1004)	No NMVr (n=1004)	Risk difference	Relative Risk Reduction	Odds ratio	P-value
			Primary Outcome			
Broadly defined PASC	273	347	-0.074 (-0.114, -0.033)	21.33%	0.707 (0.585, 0.855)	< 0.001
Narrowly defined PASC	221	278	-0.057 (-0.094, -0.019)	20.50%	0.737 (0.601, 0.903)	0.003
		S	Secondary Outcomes			
		I	ndividual Symptoms			
Constitutional symptoms	108	128	-0.018 (-0.046, 0.010)	15.63%	0.840 (0.639, 1.104)	0.211
CV and respiratory symptoms	130	171	-0.041 (-0.072, -0.010)	23.98%	0.725 (0.566, 0.928)	0.010
Gastrointestinal symptoms	103	151	-0.048 (-0.077, -0.019)	31.79%	0.646 (0.494, 0.844)	0.001
Nervous system and MSK symptoms	46	54	-0.008 (-0.027, 0.011)	14.81%	0.845 (0.564, 1.264)	0.412
Anxiety/mood disorder related symptoms	157	211	-0.054 (-0.088, -0.020)	25.59%	0.697 (0.555, 0.875)	0.002
		Н	lealthcare Utilization			
Radiology diagnostic tests	151	203	-0.052 (-0.085, -0.019)	25.62%	0.698 (0.554, 0.881)	0.002
CV tests (Echocardiogram and ambulatory rhythm monitors)	20	38	-0.018 (-0.033, -0.003)	47.37%	0.517 (0.298, 0.894)	0.016
AMB/Virtual Visit	574	622	-0.048 (-0.091, -0.005)	7.72%	0.820 (0.686, 0.980)	0.029

 $Abbreviations: ER-Emergency\ Room,\ GI-Gastrointestinal$



Outcomes (30-180 days)	OR (95% CI)	p-value	
Primary outcomes			
Broadly defined PASC	0.80(0.67-0.95)	0.014	
Narrowly defined PASC	0.75(0.62-0.90)	0.002	
Secondary outcomes			
Individual symptoms			
Constitutional symptoms	0.92(0.73-1.15)	0.491	-
CV and respiratory symptoms	0.72(0.58-0.88)	0.001	-
Gastrointestinal symptoms	0.79(0.63-0.98)	0.036	
Nervous system and MSK symptoms	0.80(0.57-1.1)	0.185	-
Anxiety or mood disorder	0.77(0.63-0.94)	0.011	
Healthcare utilization			
Radiology diagnostic tests	0.83(0.68-1.01)	0.067	-
Cardiovascular tests	0.59(0.39-0.87)	0.008	
Ambulatory or Virtual visits	1.00(0.8-1.2)	0.959	-
			0.2 0.4 0.6 0.8 1 1.2

Outcomes (90-180 days)	OR (95% CI)	p-value	
Primary outcomes			
Broadly defined PASC	0.71(0.58-0.85)	0.001	
Narrowly defined PASC	0.74(0.60-0.90)	0.003	
Secondary outcomes			
Individual symptoms			
Constitutional symptoms	0.84(0.64-1.10)	0.211	
CV and respiratory symptoms	0.72(0.56-0.93)	0.01	
Gastrointestinal symptoms	0.65(0.49-0.84)	0.001	
Nervous system and MSK symptoms	0.84(0.56-1.26)	0.412	-
Anxiety or mood disorder	0.69(0.55-0.87)	0.002	
Healthcare utilization			
Radiology diagnostic tests	0.69(0.55-0.88)	0.002	
Cardiovascular tests	0.51(0.29-0.89)	0.016	
Ambulatory or Virtual visits	0.82(0.68-0.98)	0.029	
			0.2 0.4 0.6 0.8 1 1.2